Drawing for STEMPACK

USPTO serial 79115376

STEMPACK

Reviewed by CopyMark Law Group

Reg. 4359613Status 709
Filing date
Status date
Registration date
Jul 2, 2013
Examiner
MARTIN, CHRISTINE C
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with STEMPACK?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jonathan Myers

Jonathan Myers KF ROSS, P.C.5720 Mosholu Ave.P.O. BOX 900Bronx, NY 10471-0900

Goods and services

ClassDescriptionStatusFirst use
005Biological preparations intended for use in cell cultures; Cellular media cultures for cultivating stem cells; Culture media for cell growth, namely, culture media for cultivating stem cells intended for medical biotechnology; Biological reagents for molecular biology, chemical reagents for medical use for biological processes, carriers of culture media for medical use, namely, Iscove's modified Dulbecco's medium, used for rapidly proliferating high density cell cultures; Cellular function activating agents, namely, cell growth factors and hematopoietic factors; Medicated serums, namely, human serums for cell culture; Antibodies, namely, monoclonal antibodies for the selection and purification of stem cells; All of the aforementioned goods being for medical useSECTION 71 - CANCELLED—
010Medical apparatus and instruments exclusively for cellular therapy, medical apparatus for cell culture, medical instruments for cell culture, medical apparatus and devices for cell separation techniquesSECTION 71 - CANCELLED—
042Research and development of new products in the field of biotechnology, scientific analysis for medical purposes and for development of new products for medical research for othersSECTION 71 - CANCELLED—
044Medical care and treatment; Medical services, namely, collecting, isolating and growing cells for medical purposes; Medical analysis services relating to treating individuals, namely, in vitro diagnostic, testing and statistic analysis of the patient status for medical purposes; Therapeutic treatmentsSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 17, 2022FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 21, 2022RNWLINTERNATIONAL REGISTRATION RENEWED—
Jul 21, 2022LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Jul 3, 2022LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Feb 27, 2022GPNXNOTIFICATION PROCESSED BY IB—
Dec 12, 2021RFNTREFUSAL PROCESSED BY IB—
Nov 28, 2020INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Oct 30, 2020INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Oct 30, 2020INPCINVALIDATION PROCESSED—
Oct 7, 2020INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Feb 7, 2020C71TCANCELLED SECTION 71—
Feb 6, 2020NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 22, 2019ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Aug 1, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 2, 2018REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Nov 16, 2013FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 7, 2013FICSFINAL DISPOSITION NOTICE SENT TO IB—
Oct 7, 2013FIMPFINAL DISPOSITION PROCESSED—
Oct 2, 2013FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jul 2, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 18, 2013GPNXNOTIFICATION PROCESSED BY IB—
Apr 16, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 16, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 27, 2013OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 27, 2013OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 27, 2013NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 13, 2013PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Mar 13, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 12, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 11, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 11, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 6, 2013ALIEASSIGNED TO LIE—
Mar 5, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 23, 2012RFNTREFUSAL PROCESSED BY IB—
Sep 5, 2012RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 4, 2012RFRRREFUSAL PROCESSED BY MPU—
Aug 31, 2012RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 30, 2012CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 28, 2012DOCKASSIGNED TO EXAMINER—
Aug 14, 2012MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 10, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 9, 2012REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance